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Objective: Autonomic neuropathy is a major component of familial amyloid polyneuropathy (FAP) due to mutated
transthyretin, with sudomotor failure as a common manifestation. This study aimed to investigate the pathology and
clinical significance of sudomotor denervation.
Methods: Skin biopsies were performed on the distal leg of FAP patients with a follow-up duration of 3.86 1.6
years. Sudomotor innervation was stained with 2 markers: protein gene product 9.5 (PGP 9.5), a general neuronal
marker, and vasoactive intestinal peptide (VIP), a sudomotor nerve functional marker, followed by quantitation
according to sweat gland innervation index (SGII) for PGP 9.5 (SGIIPGP 9.5) and VIP (SGIIVIP).
Results: There were 28 patients (25 men) with Ala97Ser transthyretin and late onset (59.966.0 years) disabling neu-
ropathy. Autonomic symptoms were present in 22 patients (78.6%) at the time of skin biopsy. The SGIIPGP 9.5 and
SGIIVIP of FAP patients were significantly lower than those of age- and gender-matched controls. The reduction of
SGIIVIP was more severe than that of SGIIPGP 9.5 (p50.002). Patients with orthostatic hypotension or absent sym-
pathetic skin response at palms were associated with lower SGIIPGP 9.5 (p5 0.019 and 0.002, respectively). SGIIPGP
9.5 was negatively correlated with the disability grade at the time of skin biopsy (p5 0.004), and was positively corre-
lated with the interval from the time of skin biopsy to the time of wheelchair usage (p50.029).
Interpretation: This study documented the pathological evidence of sudomotor denervation in FAP. SGIIPGP 9.5
was functionally correlated with autonomic symptoms, autonomic tests, ambulation status, and progression of
disability.
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Familial amyloid polyneuropathy (FAP) due to trans-thyretin (TTR) mutations is a relentless disease
affecting the peripheral nervous system and vital organs.1
There are >100 point mutations of TTR with ethnic
preferences.2 For example, Val30Met is the most com-
mon point mutation in Western countries and Japan,3 as
is Ala97Ser in Taiwan.4 FAP typically results in a gener-
alized disabling neuropathy affecting the autonomic,
sensory, and motor components of the peripheral nerve
system.
Autonomic neuropathies involving various organ
systems are important and can sometimes be early clini-
cal presentations of FAP. Sudomotor failure is a major
component of autonomic neuropathy.1,5 Most clinical
evaluations of autonomic neuropathy depend on func-
tional tests; there is, however, a lack of pathological
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examinations to demonstrate the degeneration of the
peripheral autonomic nerves in FAP. Because sweat
glands are located in the dermis, this anatomical position
offers potential to evaluate nerve fibers innervating sweat
glands via skin biopsy. We, and several groups, have
developed a morphometric analysis method to quantify
the pathology of sudomotor innervation from skin biop-
sies, that is, a sweat gland innervation index (SGII).6,7
Sudomotor innervation is reduced in diabetes7,8 and cor-
related with the symptoms of diabetic autonomic neu-
ropathy.9 In FAP, however, the pathology of sudomotor
innervation and its clinical significance remained unclear;
given that autonomic dysfunction was a major symptom.
Traditionally, sudomotor nerve innervation is examined
with a general neuronal marker of protein gene product
9.5 (PGP 9.5).6,7 A further critical issue is whether there
exists sudomotor innervation of different phenotypes
showing different innervation patterns, for example, vaso-
active intestinal peptide (VIP).10
This study aimed to investigate the pathology of
sweat gland innervation in FAP of TTR Ala97Ser by
analyzing the phenotypes of sweat gland innervation with
2 different markers: a general neuronal marker PGP 9.5,
and a sudomotor nerve marker VIP. Specifically, we
examined the clinical significance of the sudomotor
degeneration in relation to (1) neurological symptoms,
(2) autonomic functional tests, and (3) functional deficits
of disability grade.
Subjects and Methods
Participants
Patients with TTR Ala97Ser mutation and polyneuropathy
were identified from the database of the Department of Neurol-
ogy, National Taiwan University Hospital, Taipei, Taiwan from
January 1, 2000 to December 31, 2013. Patients were regularly
followed at our hospital, and clinical information including all
relevant examinations was retrieved. All had received complete
workup for the diagnosis of polyneuropathy including physical
and neurological examinations, laboratory tests, nerve conduc-
tion studies, quantitative sensory testing, autonomic function
tests, and skin biopsy. The inclusion criteria consisted of: (1)
length-dependent neuropathy with clinical evidence of limb
weakness and sensory symptoms, (2) electrophysiological evi-
dence of axonal polyneuropathy on nerve conduction studies,
and (3) TTR Ala97Ser mutation. Patients with concomitant
systemic diseases were excluded from further analyses. Exclusion
criteria included diabetes mellitus, chronic kidney disease, syph-
ilis, human immunodeficiency virus infection, autoimmune dis-
eases, malignancies, history of using neurotoxic medications,
alcoholism, or toxin exposure as determined by detailed history
and the results of relevant laboratory tests including hematolog-
ical, biochemical, endocrine, infection, malignancy, nutritional,
and autoimmune profiles. After enrollment, clinical and
laboratory data were retrieved for further analysis. The disability
was evaluated according to the polyneuropathy disability score
on a scale of 1 to 4: grade 1, sensory symptoms without motor
disturbances; grade 2, minor motor disturbances and ability to
walk without aids; grade 3, major motor disturbances and
requiring support to walk; grade 4, confinement to a bed or a
wheelchair.11
For comparison of sweat gland innervation with the FAP
group, age- and gender-matched subjects were retrieved from
our database. Skin biopsy was performed after informed consent
was obtained from the patients. The protocol was approved by
the Ethics Committee of National Taiwan University Hospital,
Taipei, Taiwan.
Nerve Conduction Studies
Nerve conduction studies were performed with a Nicolet (Mad-
ison, WI) Viking IV Electromyographer on all patients as per
standardized methods.12 The amplitude of the sural sensory
action potentials (SAP) and the amplitude of the compound
muscle action potentials (CMAPs) on distal stimulation from
the peroneal nerve were analyzed.
Quantitative Sensory Testing
Quantitative sensory testing was performed to measure the sen-
sory thresholds of warm/cold and vibratory sensations with a
Thermal Sensory Analyzer and a Vibratory Sensory Analyzer
(Medoc Advanced Medical System, Minneapolis, MN), respec-
tively. These procedures have been detailed previously.13,14 The
level method was the algorithm used to measure thermal
thresholds. The skin of the foot dorsum was the test site. Ther-
mal thresholds were expressed as warm threshold temperature
and cold threshold temperature. Vibratory thresholds were
measured with similar algorithms at the lateral malleolus, and
were expressed in micrometers. These measured thresholds were
compared with normative values for age.
Autonomic Function Tests
R-R interval variability (RRIV) for the cardiac–vagal function
and sympathetic skin response (SSR) for the sudomotor func-
tion were performed using established protocols on the Nicolet
Viking IV Electromyographer.15 The RRIV was obtained dur-
ing rest position and forced deep breathing. Each test was
repeated 3 times, and the mean value was compared with that
for the age-matched controls in our laboratory. SSR was
recorded in the palm and sole, and the results were interpreted
as present or absent, but were not evaluated quantitatively
because of variations in the latencies and the amplitudes of
SSR.
Skin Biopsy
Skin biopsy was performed by following established procedures
after informed consent had been obtained.16,17 A 3mm diame-
ter skin punch was taken from the distal leg 10cm proximal to
the lateral malleolus under local anesthesia with 2% lidocaine.
All patients tolerated the procedure with no obvious discomfort.
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In the present study, the skin biopsy of all patients were per-
formed between 2000 and 2010 (median year5 2007).
Immunohistochemistry of Sweat Gland and
Epidermal Innervation with PGP 9.5
Skin sections were immunostained with PGP 9.5 to demon-
strate nerve fibers, and then counterstained with Congo red to
reveal sweat glands as described previously.9 In brief, the sam-
pled skin tissue was fixed overnight in 2% paraformaldehyde-
lysine-periodate. Sections of 50lm perpendicular to the dermis
were immunostained with rabbit antiserum to PGP 9.5
(1:1,000; UltraClone, Isle of Wight, UK). Biotinylated goat
antirabbit immunoglobulin G (Vector Laboratories, Burlin-
game, CA) and the avidin–biotin complex (Vector Laboratories)
were sequentially applied. The reaction product was demon-
strated with chromogen SG (Vector Laboratories). The sections
were termed “conventional sections.” Additional conventional
sections were further counterstained with 1% Congo red (Muto
Pure Chemicals, Tokyo, Japan) for 5 minutes to reveal the terri-
tory of the sweat gland. Sections were dehydrated with anhy-
drated alcohol and mounted using DPX (Sigma, St Louis,
MO), a nonaqueous synthetic resin. Congo red staining showed
well-defined areas of sweat glands and thus facilitated measure-
ments of sweat gland area.6 We quantified the epidermal inner-
vations on conventional sections and the sweat gland
innervation on the Congo red–counterstained sections.
To understand the nature of Congo red staining in sweat
glands, we observed sections under polarized microscopy.
Because some of these patients received sural nerve biopsy for
diagnostic purpose, we retrieved 3 sural nerve biopsies of FAP
for comparison.
Quantitation of Sweat Gland Innervation by
PGP 9.5 Immunohistochemistry and Congo Red
All identifying information on the slides was masked before
quantification. Sections were observed under a 320 objective
on a DM2500 light microscope (Leica Microsystems, Wet-
zlar, Germany) equipped with a DFC490 charge-coupled
device (Leica Microsystems). The acquired image was then
opened with Photoshop CS3 (Adobe Systems, San Jose, CA)
to quantitate sweat gland innervation. The areas of PGP
9.51 nerve fibers and Congo red–stained sweat glands were
measured on each section. We designated SGII of the
selected sweat gland according to the formula: SGII5nerve
fiber area/sweat gland area 3 100%, which represented the
area of nerve fibers normalized to the area of the sweat
gland according to our previous report of quantifying sweat
gland innervations.9 The mean of all SGIIs (3–7 sweat
glands from 3 different sections for each subject) was
defined as the SGII of a given subject. The normative val-
ues of SGII based on PGP 9.5 staining (SGIIPGP 9.5;
mean6 standard deviation [SD], 5th percentile) from our
laboratory were 4.33%6 1.32%, 2.36% for males and
5.33%6 1.41%, 2.69% for females.9 SGIIPGP 9.5 was clas-
sified as abnormal if SGIIPGP 9.5 was <2.36% and
<2.69% for males and females, respectively.
Immunohistochemistry and Quantitation of
Sweat Gland Innervation with VIP
For demonstrating sweat glands and functional markers of
sudomotor nerves, additional sections were stained with double
immunofluorescence: Na-K-Cl cotransporter (NKCC1) for
sweat gland cells, and VIP for sudomotor nerves. Sections were
incubated with mouse NKCC1 antiserum (clone T4, 1:500;
Developmental Studies Hybridoma Bank, Iowa City, IA) and
rabbit VIP antiserum (1:100; ImmunoStar, Hudson, WI) over-
night. Signals of NKCC1 and VIP were visualized with Cy3
(1:100; Jackson ImmunoResearch, West Grove, PA) and fluo-
rescein isothiocyanate (FITC; 1:100, Vector Laboratories),
respectively. After rinsing, sections were mounted with 2% n-
propyl gallate in 60% glycerol. The immunofluorescent sections
were observed under a 320 objective (with oil) on a confocal
microscope (TCS SP5, Leica Microsystems). The Cy3 signals
(for sweat glands) and FITC signals (for nerve fibers) were
imaged after excitation with a HeNe543 laser and an argon488
laser, respectively. The images were obtained through z-section
stacking, which overlapped a series of phases scanned along the
z-axis of the skin section. The acquired images were merged for
colocalization of the sweat glands and their surrounding nerve
fibers on skin sections. At least 3 qualified sweat glands from
all skin sections were used for the quantitative analysis of a
given subject as in our previous report.6
The acquired images were opened in Photoshop CS3.
On each section, the areas of sweat glands (in red) and the
nerve fibers (in green) were measured separately. For measuring
sweat gland areas, the “select/color range” command (the magic
wand tool) was used (under the red channel), which determined
the margins of sweat glands automatically without manual trac-
ing by the operator. The sum of pixel values of the selected
areas represented the sweat gland areas. Under the green chan-
nel, the same “select/color range” command was applied to
measure the area of surrounding nerve fibers. The selected pixel
values represented the nerve fiber areas. The derived SGII was
the nerve fiber area normalized by the sweat gland area (as a
percentage) for the given sweat gland. The mean of all SGIIs
was defined as the SGII of VIP (SGIIVIP) for a given subject
as described in SGIIPPGP 9.5.6 The normative values of SGII-
VIP (mean6 SD, 5th percentile) from our laboratory were
3.17%6 2.38%, 0.95% for males, and 5.52%6 3.67%, 1.04%
for females. SGIIVIP was classified as abnormal if SGIIVIP was
<0.95% and <1.04% for males and females, respectively.
Quantification of Epidermal Innervation
Epidermal innervation was quantified from the conventional
sections according to established criteria in a coded fashion
with the examiners blinded to the clinical information. PGP
9.5–immunoreactive nerve fibers in the epidermis of each sec-
tion were counted at a magnification of 340 with an BX40
microscope (Olympus, Tokyo, Japan) through the depth of the
entire section. Intraepidermal nerve fiber (IENF) density was
therefore derived and expressed as the number of fibers/mm of
the epidermal length. In the distal leg, normative values from
our laboratory (mean6 SD, 5th percentile) for IENF were
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11.166 3.70, 5.88 fibers/mm for subjects aged <60 years and
7.646 3.08, 2.50 fibers/mm for subjects aged 60 years.18
The cutoff point of IENF density was 5.88 and 2.50 fibers/mm
in these 2 age groups, respectively.
Immunohistochemistry of TTR
To examine whether amyloid was on the skin biopsies and to
test whether amyloid was related to TTR, we performed TTR
immunohistochemistry on skin and sural nerve biopsies follow-
ing the same protocols described in the preceding sections with
modifications; that is, anti-TTR antiserum (1:500; Dako,
Glostrup, Denmark) and chromogen 3,30-diaminobenzidine
(Sigma) were used.
Statistical Analysis
Numerical variables were expressed as the mean6 SD, and
were compared with t tests if the data followed a Gaussian dis-
tribution. If the sample size was small, the numerical variables
were compared using a nonparametric test (Wilcoxon rank sum
test). Fisher exact test was used to compare categorical data.
Correlations between variables were graphically analyzed using
Stata (StataCorp, College Station, TX) and Prism (GraphPad
Software, San Diego, CA). For analysis of the degree of sudo-
motor innervation, SGIIPGP 9.5 and SGIIVIP of each patient
were converted to a percentile rank as an additional parameter
according to the normative data of SGIIPGP 9.5 and SGIIVIP,
respectively. Results were considered significant at p< 0.05.
Results
Clinical Presentations
There were 28 patients (25 men, Supplementary Table)
with genetic confirmation of the Ala97Ser mutation in
the TTR gene, and all had clinical and electrophysiologi-
cal evidence of polyneuropathy. The onset of neuropathic
symptoms was at the age of 59.96 6.0 (range5 48–71)
years. The duration between the onset of neuropathic
symptoms and the clinical evaluation with skin biopsy
was 2.36 1.2 (range5 1–5) years. At the time of skin
biopsy, autonomic symptoms were present in 22 patients
(78.6%), and included gastrointestinal, cardiovascular,
genitourinary, and sweating dysfunctions. All patients
had difficulties in ambulation: grade II (21), grade III
(6), and grade IV (1). Paresthesia was present in all
patients, with 15 of them (53.6%) having neuropathic
pain. Sensations of large and small fibers were impaired.
During the follow-up (3.86 1.6 years after skin biop-
sies), all patients had a progressive course leading to dis-
ability, with the interval from symptom onset to the time
with a grade IV (wheelchair usage) disability being
4.46 1.6 (range5 2–8) years.
Electrophysiological Studies
To understand the global physiological picture of FAP, we
conducted autonomic function tests (SSR and RRIV) and
nerve conduction studies. SSR was absent in the palms of 9
patients (32.1%), and in the soles of 22 patients (78.6%).
Except for 3 patients with arrhythmia during the tests,
RRIV was reduced at rest and during deep breathing in 22
patients (88%). In total, 25 patients (89.3%) had abnor-
malities in at least 1 autonomic functional test at the time
of clinical evaluation. Nerve conduction studies showed
sensorimotor polyneuropathy of axonal degeneration pat-
tern in all patients. Quantitative sensory testing showed ele-
vated thermal thresholds in 24 patients and elevated
vibratory thresholds in all patients, indicating impaired sen-
sory functions of both large and small sensory nerves.
TTR Amyloid Detection in Skin and Nerve
Biopsies
In the Congo red–stained sections under polarized light
microscopy, typical amyloids in the vascular wall of an
endoneurial arteriole on sural nerve biopsies showed
apple-green birefringence (Fig 1A, B). In contrast, sweat
glands on skin sections did not reveal such a pathognomic
pattern of amyloids. In the skin biopsies of all patients,
we only detected Congo red1 materials in the arteriole of
a small dermal nerve bundle with yellow birefringence
from 1 patient (see Fig 1C–F). Congo red binds the sec-
ondary structures of a variety of chemicals, including amy-
loids of TTR or amyloid precursor protein,19 variable
native proteins,20 and lipopolysaccharides in bacteria
Shigella.21 Some of these complexes exhibit dichromatic
spectrum under polarized microscopy depending on their
chemical natures, for example, apple-green birefringence in
amyloids.20,22 In this study, the pattern of Congo red stain-
ing in sweat glands was different from that of amyloids;
that is, amyloids in small arterioles of sural nerve biopsies
showed typical apple-green birefringence, which was absent
in Congo red–stained sweat glands of skin biopsies.
We further examined whether amyloid was related
to TTR by immunohistochemistry with anti-TTR anti-
body. TTR immunoreactivity was documented in the
amyloids surrounding endoneurial arterioles in sural nerve
biopsies (Fig 2A, B), confirming the nature of TTR-
related amyloids. Skin sections from the patient described
in Figure 1E and F were further stained with PGP 9.5,
TTR, and Congo red (see Fig 2C–F). There were scanty
PGP 9.51 periglandular nerve fibers and fragmented nerve
fibers in dermal nerve bundles. The Congo red counter-
staining in sweat glands exhibited red autofluorescence.
There was no TTR immunoreactivity in Congo red–
stained sweat glands. Thus specific TTR immunoreactivity
was not detected in the skin of FAP patients. These find-
ings demonstrated that the pathogenic roles of TTR in
amyloids and Congo red–stained sweat glands were inde-
pendent of TTR. The absence of specific TTR
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immunoreactivity in skin biopsies may reflect a very low
prevalence of amyloids in the skin of FAP.
Sweat Gland and Epidermal Innervation Based
on PGP 9.5 Staining
To investigate the pathology of sweat gland innervation,
we first examined this issue by staining skin biopsies with
PGP 9.5 according to conventional methods.23 In the der-
mis of the control skin, PGP 9.51 nerve fibers appeared
as a dense and linear pattern circling the sweat glands,
which had mild staining intensity higher than the back-
ground and much lower than the staining intensity of
nerve fibers as described before.6,7 In the skin of FAP
patients, the PGP 9.51 nerve fibers surrounding sweat
glands were markedly decreased (Fig 3A, B).
FIGURE 1: Congo red staining and polarized microscopic examinations of sural nerve and skin biopsies from patients with fami-
lial amyloid polyneuropathy (FAP). Sections of sural nerve (A, B) and skin (C–F) biopsies were stained with Congo red (A, C,
and E) and observed under a polarized microscope (B, D, and F). (A, B) Congo red–stained materials in an arteriole of the sural
nerve exhibited apple-green birefringence under polarized microscopy. (C, D) Secretory coils of sweat glands were stained
with Congo red (arrow) but did not show birefringence under polarized microscopy. (E, F) In a dermal nerve bundle from an
FAP patient, Congo red1 materials were detected surrounding a small arteriole (arrow), which showed birefringence under
polarized microscopy. Scale bar550lm for A and B, 200lm for C and D, and 25lm for E and F.
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In the epidermis of the control skin, there were dis-
tinct varicose IENFs and subepidermal nerve plexuses
appearing as dense nerve bundles. In the epidermis of
the FAP skin, nearly all IENFs were depleted, and nerve
fibers with a fragmented profile in the dermal nerve bun-
dles were observed (see Fig 3C, D).
To make the sweat glands clear for quantifying
sweat gland area as the denominator of SGII, we per-
formed PGP 9.5 immunohistochemistry and counter-
stained with Congo red for sweat glands.9 In the dermis
of the control skin, sweat glands appeared as red coils
and sudomotor nerves were demonstrated with dense
PGP 9.51 fibers forming linear and varicose patterns cir-
cling the secretary coils of sweat glands (Fig 4A). These
patterns represented nerve trunks and the terminal parts
of sudomotor nerves. In FAP patients, there was signifi-
cant reduction of nerve fibers innervating sweat glands
and only a small portion of the entire sweat glands was
surrounded by nerve fibers, indicating nerve degeneration
(see Fig 4B).
Sweat Gland Innervation Based on VIP-NKCC1
Staining
To further examine the changes in the phenotypic pat-
terns of sweat gland innervation, we performed immuno-
fluorescence staining of skin biopsies with VIP for
sudomotor nerve fibers, and NKCC1, a transporter
protein located in sweat gland cells, for sweat glands.24
In the dermis of the control skin, the sweat glands
appeared as red tubular structures surrounded by VIP1
sudomotor nerve fibers with dense linear and circular
patterns (Fig 5A–C). In FAP patients, only scanty VIP1
sudomotor nerve fibers with fragmented and dotted pat-
terns innervating sweat glands were seen, indicating sudo-
motor degeneration (see Fig 5D–F).
Quantitative Analysis of Sudomotor and Skin
Innervation in FAP
To quantitatively analyze the above observations, we
compared the innervation of sweat glands and epidermis
of FAP patients with age- and gender-matched controls
(Fig 6 and Supplementary Table). The SGIIPGP 9.5 in
the FAP group was significantly lower than that in the
control group (1.85%6 1.05% vs 4.67%6 1.31%,
p< 0.001), and 18 patients (64.3%) had reduced
SGIIPGP 9.5. The SGIIVIP in the FAP group was also
significantly lower than that in the control group
(0.11%6 0.16% vs 3.84%6 2.48%, p< 0.001). SGII-
VIP was reduced in all patients (100%), indicating that
the frequency of sudomotor denervation was higher in
VIP than in PGP 9.5. We further explored the degree of
sudomotor denervation by analyzing the percentile rank
of SGII in the normative database between VIP1 and
PGP 9.51 nerves. The depletion of VIP1 sudomotor
FIGURE 2: Transthyretin (TTR) expression in sural nerve and skin biopsies in familial amyloid polyneuropathy (FAP). Sections of
sural nerves (A, B) were stained with hematoxylin and eosin (H&E; A) and immunohistochemistry of TTR (B), respectively. Immu-
nofluorescent staining with protein gene product 9.5 (PGP 9.5; labeled with green fluorescence in C) and TTR (labeled with
blue fluorescence in E) followed with Congo red counterstaining (with red autofluorescence in D) was performed on the skin
biopsy from the same FAP patient in Figure 1C to F. (A, B) There was TTR immunoreactivity in amyloid with eosinophilic amor-
phous appearance surrounding an arteriole from sural nerve biopsy. (C–F) Scanty PGP 9.51 nerve fibers were detected sur-
rounding sweat glands, which exhibited red autofluorescence after Congo red staining. In these Congo red–stained sweat
glands, there was no TTR immunoreactivity. Scale bar5100lm in B applied to A and B, 50lm in F applied to C–F.
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nerves was more extensive than that of PGP 9.51 sudo-
motor nerves (0.16 0.5 percentile vs 6.36 9.8 percen-
tile, p5 0.002). There was no correlation between
SGIIPGP 9.5 and SGIIVIP (p5 0.971).
The IENF density of FAP patients was markedly
reduced compared to that of the control subjects
(1.116 1.32 vs 8.076 2.83 fibers/mm, p< 0.001; see
Fig 6C), and the IENF density was reduced in 26
patients (92.9%).
Clinical Significance of Sweat Gland Innervation
To understand the clinical significance of sweat gland
innervation, we explored the relationship of sweat gland
innervation with clinical parameters: (1) autonomic symp-
toms and functional tests (Fig 7A, B) and (2) disability
grade (see Fig 7C, D). Among autonomic symptoms, the
SGIIPGP 9.5 was reduced in patients with orthostatic
hypotension compared to those without orthostatic hypo-
tension (1.33%6 0.97% vs 2.25%6 0.95%, p5 0.019).
For autonomic functional tests, SGIIPGP 9.5 was related
to the SSR at the palm: lower in patients with absent
SSR at the palm than in those with present SSR at the
palm (1.03%6 0.68% vs 2.25%6 0.97%, p5 0.002).
Furthermore, the SGIIPGP 9.5 was negatively correlated
with the disability grade at the time of skin biopsy
(r521.03, p5 0.004), and was positively correlated
with the interval from the time of skin biopsy to the
time of wheelchair usage (r5 0.33, p5 0.029), indicat-
ing that a lower SGIIPGP 9.5 was associated with higher
disability grade at the time of skin biopsy and more
rapid progression of disability during follow-up. There
was no correlation of SGIIVIP with autonomic symp-
toms, the disability at the time of skin biopsy, or the
progression of disability. We also explored the relation-
ship of the IENF density and parameters of nerve con-
duction studies with these disability indexes. The IENF
density and the SAP of sural nerves had no correlation
with the disability grade at skin biopsy or further
FIGURE 3: Sweat gland and skin innervation in familial amyloid polyneuropathy (FAP) due to transthyretin Ala97Ser mutation.
Skin sections from control subjects (A and C) and patients with FAP (B and D) were immunostained with protein gene product
9.5. (A) In the control skin, the sudomotor nerve fibers appeared as dense immunoreactivities with a circular pattern surround-
ing the secretary coils of sweat glands. (B) The nerve fibers surrounding sweat glands in FAP patients were markedly reduced,
and only some loose and fragmented immunoreactivities could be observed. (C) In the control skin, intraepidermal nerve fibers
(arrow) with a varicose appearance ascended from the subepidermal nerve plexus (snp) at the border of the epidermis (epi)
and dermis (derm). Dermal nerve fascicles (d.n.) exhibited a pattern of linear and dense immunoreactivities in the deep dermis.
(D) Intraepidermal nerve fibers disappeared in the skin of FAP patients and dermal nerves became fragmented, indicating
nerve degeneration. Scale bar545lm for A and B, 20lm for C and D.
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progression of the disability grade. The CMAP amplitude
of peroneal nerve was negatively correlated with the dis-
ability grade at the time of skin biopsy (r520.65,
p5 0.004), and was positively correlated with the inter-
val from the time of skin biopsy to the time of wheel-
chair usage (r5 0.28, p5 0.002).
Discussion
The study applied 2 different makers, PGP 9.5 and VIP,
to demonstrate the pathologic evidence of sudomotor
denervation in FAP and the clinical significance related
to autonomic symptoms and autonomic functional tests.
Furthermore, the degree of sweat gland innervation by
FIGURE 5: Sweat gland innervations in familial amyloid polyneuropathy (FAP). Skin sections were immunostained with vasoac-
tive intestinal peptide (VIP; green) for sudomotor nerves (A and D), and Na-K-Cl cotransporter (NKCC1, red) for sweat glands
(B and E). (A–C) In the control skin, the sudomotor nerve fibers were labeled by VIP immunoreactivities with linear and circular
patterns (A) and the sweat gland was labeled by NKCC1 immonoreactivities as red coils (B). The sudomotor nerve fibers
encircled the secretary coils of the sweat gland (C). (D–F) In FAP patients, the innervation of sweat glands by VIP1 nerves (D)
surrounding NKCC11 sweat glands (E) was significantly reduced. Only scattered VIP immunoreactivities surrounded the secre-
tary coils of the sweat gland (F). Scale bar5100lm.
FIGURE 4: Sweat gland innervations in familial amyloid polyneuropathy (FAP). Skin sections were immunostained with protein
gene product 9.5 (PGP 9.5) antiserum and then counterstained with Congo red. (A) In the control skin, sweat glands appeared
as red coils and were surrounded by the linear and varicose sudomotor nerve fibers of dense PGP 9.5 immunoreactivities. (B)
The sweat gland innervation was markedly reduced in FAP, and only some scattered and fragmented immunoreactivities sur-
rounding a small portion of the sweat gland could be observed, indicating sudomotor nerve degeneration. Scale bar550lm.
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FIGURE 7: The clinical significance of sudomotor innervation in familial amyloid polyneuropathy. (A) The comparison of sudo-
motor innervation was made between patients with and without orthostatic hypotension. The sweat gland innervation index
by protein gene product 9.5 immunostaining (SGIIPGP 9.5) was lower in patients with orthostatic hypotension (Ortho Hypo)
than those without this symptom. (B) The SGIIPGP 9.5 was lower in patients with absent sympathetic skin response at the
palm than in those with present response, reflecting the relationship between the pathology and functional consequence of
sudomotor denervation. (C, D) SGIIPGP 9.5 was negatively correlated with the disability grade at the time of skin biopsy (C)
and positively correlated with the time from skin biopsy to loss of ambulation ability (D), indicating the lower sudomotor inner-
vation, the higher grade, and the more rapid progression of disability. SSR5 sympathetic skin response at palm;15 pre-
sence;25 absence. *p<0.05, **p<0.005.
FIGURE 6: Quantitation of sweat gland and skin innervation in familial amyloid polyneuropathy (FAP). Quantitative data of
sweat gland and skin innervation were analyzed according to: (A) the sweat gland innervation index by protein gene product
9.5 immunostaining (SGIIPGP 9.5), (B) the sweat gland innervation index by vasoactive intestinal peptide immunostaining (SGII-
VIP), and (C) the intraepidermal nerve fiber (IENF) density. All 3 parameters were significantly reduced in the FAP group com-
pared to the age- and gender-matched control subjects. **p<0.005.
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PGP 9.51 nerves serves as a prognostic factor for the
progression of the disability grade, suggesting that com-
bining SGII and IENF density, skin biopsy provides a
new window to evaluate the general conditions of FAP.
Pathologic Evidence of Sweat Gland
Denervation
The current report documents quantitative evidence of
sudomotor nerve degeneration in FAP, that is, reduced
SGIIPGP 9.5 and SGIIVIP, which corroborate the func-
tional impairment of SSR. Previous investigations of
autonomic failure in FAP heavily depended on functional
evaluations or image studies. For example, SSR was
abnormal in FAP due to Val30Met mutation.25,26 Com-
bined examinations using capsule polyhydrography and
computer analysis of the cardiographic R-R intervals
indicated the early involvement of peripheral autonomic
functions in the Val30Met variant.27 Iodine-123 metaio-
dobenzylguanidine (MIBG) scintigraphy revealed reduced
myocardial uptake in FAP, suggesting myocardial sympa-
thetic denervation.28,29 However, there was limited path-
ologic evidence demonstrating the denervation of
autonomic targets, such as a report on postmortem tis-
sues, which showed amyloid depositions and neuronal
cell loss in sympathetic ganglia with microscopic resolu-
tion.2,30 Sweat gland innervation was reduced in type 2
diabetic neuropathy,6,7,9 and we have documented that
this reduction of SGIIPGP 9.5 was attributed to sudo-
motor nerve degeneration as demonstrated at the ultra-
structural level.6 The current report is the first to provide
direct pathologic evidence of sudomotor denervation in
FAP. Taken together, these studies indicate that sudomo-
tor denervation index was sensitive in documenting path-
ologic evidence of autonomic neuropathy regardless of
underlying etiologies and thus is not specific for FAP. In
addition to our previous demonstration of reduced
IENFs as a major pathological finding on skin biopsy in
the Ala97Ser variant of FAP,4 the present study further
provides complementary evidence of sudomotor nerve
degeneration on skin biopsies.
Phenotypic Difference in Sweat Gland
Denervation
This study provides 2 markers of sweat gland innervation
to explore the clinical significance of sweat gland innerva-
tion phenotypes. Both PGP 9.51 and VIP1 sudomotor
nerves were significantly reduced in FAP patients com-
pared to the age- and gender-matched controls, with a
difference in the abnormal rate of each examination; the
frequency of reduced SGIIVIP was higher than that of
reduced SGIIPGP 9.5 (100% vs 64.3%). PGP 9.5 is a
general marker of neurons and peripheral nerve
fibers.17,31 The reduction of PGP 9.51 sudomotor nerves
reflects sudomotor nerve degeneration as shown at the
electron microscopic level.6 This suggests that PGP 9.5
may serve as a structural marker of sudomotor nerves
and VIP serves as a functional marker of sudomotor
nerves because of its coexistence with cholinergic sympa-
thetic innervation10,32 and modulation of cholinergic
responses of sweat glands.33,34 The marked reduction of
VIP1 nerves compared to moderate reduction of PGP
9.51 nerves in sweat glands in FAP suggests that a
decrease in such neuropeptide expression is far more
prevalent than the overt structural degeneration of sudo-
motor nerves.8 This observation implies that a loss of
functional marker was earlier than a loss of structural
marker. Such a difference may be in concordance with a
previous study on a mouse model of cisplatin neuropathy
that found decrease in VIP1 nerves at an early stage fol-
lowed by PGP 9.51 nerve degeneration at a later stage.35
Multiple mechanisms underlie such a time window in
the denervation of PGP 9.51 and VIP1 sudomotor
nerves, including decreased synthesis or impaired axonal
transport of neuropeptide at the early stage of FAP and
progressive axonal degeneration as the disease burden
increases.36 Furthermore, this observation raises the possi-
bility of testing whether such alterations of functional
marker VIP at the early stage are reversible as new thera-
peutic clinical trials for FAP are initiated.37–39
Clinical Significance of Sudomotor Innervation
Index
The sudomotor innervation index provides 2 lines of
clinical information: (1) autonomic dysfunctions and (2)
disability and progression of FAP. In the present study,
we used SSR testing as a surrogate marker of sweat gland
functions. The correlation between the SGIIPGP 9.5 and
the SSR at palms suggests that SGIIPGP 9.5 may under-
lie the structural basis of sudomotor dysfunctions. This
observation extends the previous findings in patients of
diabetic neuropathy that the sudomotor innervation was
concordant with symptoms of reduced sweat produc-
tion.7,9 Future studies applying quantitative sudomotor
testing such as quantitative sudomotor axon reflex test,
quantitative direct and indirect reflex testing of sudomo-
tor function, or dynamic sweat test may offer compre-
hensive functional analysis with structural parameters of
SGII.40–42 Orthostatic hypotension is a common cardio-
vascular manifestation of autonomic dysfunctions in
FAP2 and results from impaired baroreflex and cardiac
dysfunctions.43,44 FAP patients with orthostatic hypoten-
sion had low basal plasma norepinephrine levels, which
did not increase after postural change.45 Pathological and
imaging studies showed neuronal cell loss in sympathetic
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ganglia and reduction of myocardial MIBG uptake in
FAP.30,46 The concordance between the reduced
SGIIPGP 9.5 and the symptom of orthostatic hypoten-
sion in the present study indicates the synchronous
degeneration of sympathetic cholinergic and norepineph-
rinergic nerves.
The PGP 9.51 sudomotor innervation was intrigu-
ingly associated with the ambulation status at the time of
skin biopsy and the further progression of disability in
addition to the CMAP amplitude of peroneal nerves.
Such a pattern of clinical correlation indicates that the
sudomotor innervation may reflect the global status of
nerve functions and potentially serves as a prognostic
marker for the evolution of neurological disability in
FAP. In the past, only limited tools could provide prog-
nostic predictions for the long-term progression of FAP,
for example, using MIBG imaging on the Val30Met vari-
ant to show the association of lower late heart-to-
mediastinum MIBG uptake ratio with a higher 5-year
mortality rate.29 The present study highlights the poten-
tial of applying pathologic assessment of sudomotor
innervation by skin biopsies as a prognostic factor for the
current disability and progression in FAP. The association
between the SGIIPGP 9.5 and the progression of neuro-
logical disability suggest that sudomotor denervation may
reflect the underlying gross nerve degeneration.
In contrast to SGIIPGP 9.5, there was no correla-
tion between SGIIVIP and clinical parameters. This find-
ing suggests the structural degeneration (PGP 9.5)
instead of decreased neuropeptide expression (VIP) in
sudomotor nerves reflects the clinical manifestations. An
alternative explanation underlying such a lack of correla-
tion is the marked reduction of VIP1 nerves in FAP. The
percentile rank of SGIIVIP according to the normative
data was below the 1st percentile in most FAP patients.
This distribution of SGIIVIP at the markedly low level
might lessen the statistical strength of correlations with
clinical parameters.
The present study demonstrates the pathology and
its clinical significance of sudomotor denervation in the
TTR missense mutation Ala97Ser-related FAP, a late
onset generalized disabling neuropathy. Given that skin
biopsies were performed at a mean time of 2.3 years after
the symptom onset, this suggests that sudomotor nerve
degeneration had developed at an early stage of sympto-
matic FAP. Once neuropathic symptoms began, patients
lost ambulation ability within 2 to 8 years. In the present
series of patients, autonomic dysfunction was the initial
symptom in 7.1% of the patients, and 78.6% of patients
had autonomic dysfunctions at the time of skin biopsy,
suggesting common involvement of autonomic
nerves during disease progression. Given that FAP is
characterized by early and selective involvement of small-
fiber nerves,26,47 our findings suggest that skin biopsy
can provide pathological evidence for small-fiber nerve
degeneration including both thermal–nociceptive sensory
and sudomotor autonomic nerves, and can serve as a
potential tool for early detection of FAP, for example, by
the future application of skin biopsy with IENF and
SGII evaluations to asymptomatic carriers of FAP.26
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